The proposed Core B will serve three primary functions. First, it will develop nanoscale materials for drug delivery for each of the projects. This will include new nanocarriers for drug, radiopharmaceutics and protein delivery, and include cleavable multi-block HPMA copolymers (Project 6), targeted HPMA copolymer-drug conjugates (Project 9), and protein nanocarriers (Project 7, 8, and 10). Second, the Core will assist the Center's scientists in comprehensive and in-depth characterization of the nanomaterials. The combined characterization techniques include the following: dynamic light scattering;zeta-potential measurements;analytical ultracentrifugation;surface plasmon resonance;atomic force microscopy;transmission electron microscopy;inductively coupled plasma mass spectroscopy, and fluorescence spectroscopy. Third, the Core will evaluate safety of all new synthesized nanomaterials using the respective cell lines and animal models, and the Core will provide all investigators with controlled and standardized materials for biological use.

Public Health Relevance

The Nanomaterials Core utilizes the modern tools of synthetic chemistry, polymer formulation, physicochemical characterization and safety evaluation to support a multi-dimensional (material science, pharmaceutical sciences and biology) integrated program designed for the development and characterization of nanomaterials for biomedical applications.

National Institute of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
Exploratory Grants (P20)
Project #
Application #
Study Section
Special Emphasis Panel (ZGM1-TWD-Y (C2))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Nebraska Medical Center
United States
Zip Code
Macha, M A; Rachagani, S; Pai, P et al. (2015) MUC4 regulates cellular senescence in head and neck squamous cell carcinoma through p16/Rb pathway. Oncogene 34:1698-708
Macha, Muzafar A; Seshacharyulu, Parthasarathy; Krishn, Shiv Ram et al. (2014) MicroRNAs (miRNAs) as biomarker(s) for prognosis and diagnosis of gastrointestinal (GI) cancers. Curr Pharm Des 20:5287-97
Gutti, Tanuja L; Knibbe, Jaclyn S; Makarov, Edward et al. (2014) Human hepatocytes and hematolymphoid dual reconstitution in treosulfan-conditioned uPA-NOG mice. Am J Pathol 184:101-9
Yi, Xiang; Manickam, Devika S; Brynskikh, Anna et al. (2014) Agile delivery of protein therapeutics to CNS. J Control Release 190:637-63
Alakhova, Daria Y; Kabanov, Alexander V (2014) Pluronics and MDR reversal: an update. Mol Pharm 11:2566-78
Savalia, Krupa; Manickam, Devika S; Rosenbaugh, Erin G et al. (2014) Neuronal uptake of nanoformulated superoxide dismutase and attenuation of angiotensin II-dependent hypertension after central administration. Free Radic Biol Med 73:299-307
Shi, Wen; Ogbomo, Sunny M; Wagh, Nilesh K et al. (2014) The influence of linker length on the properties of cathepsin S cleavable (177)Lu-labeled HPMA copolymers for pancreatic cancer imaging. Biomaterials 35:5760-70
Gupta, Suprit; Batra, Surinder; Jain, Maneesh (2014) Antibody labeling with radioiodine and radiometals. Methods Mol Biol 1141:147-57
Nukolova, Natalia V; Oberoi, Hardeep S; Zhao, Yi et al. (2013) LHRH-targeted nanogels as a delivery system for cisplatin to ovarian cancer. Mol Pharm 10:3913-21
Zhou, Zhengyuan; Wagh, Nilesh K; Ogbomo, Sunny M et al. (2013) Synthesis and in vitro and in vivo evaluation of hypoxia-enhanced 111In-bombesin conjugates for prostate cancer imaging. J Nucl Med 54:1605-12

Showing the most recent 10 out of 16 publications